Saint-Genis-Pouilly, France, 17 June 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces that it has advanced dencatistat, the Company’s first-in-class, highly selective, oral CTPS1 inhibitor, into a phase 2 clinical trial for essential thrombocythaemia (ET), a rare clonal blood disorder characterised by overproduction of platelets and risk of thrombosis.